Blood test to monitor liver cancer return after treatment
Part of Cancer, Digestive system clinical trials.
This study uses a blood test that looks for signs of liver cancer coming back after treatment. It may help doctors find recurrence early and plan better care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have liver cancer or are suspected of having it and are about to have surgery, transplant, ablation, or chemoembolization (TACE).
- You have had treatment before but still have liver cancer and are about to have another one of these treatments.
- You have finished treatment for liver cancer and your earlier blood test for this study was positive.
- You are not planning to have any of these treatments, or your doctor cannot confirm you have primary liver cancer, so you may not be eligible.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new blood test that looks for DNA from cancer cells' mitochondria to see if it can catch liver cancer coming back earlier. The goal is to help doctors find recurrence faster and improve follow-up care.
This study looks at whether a blood test (measuring a protein called AKR1B10) can help detect if liver cancer comes back after surgery. It may help doctors monitor patients more closely after tumor removal.
This study looks at blood tests to see if they can predict how well liver cancer responds to a procedure called TACE. Participation involves giving blood samples and having your normal follow-up scans.
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
This trial uses a blood test to check for signs of liver cancer coming back after treatment. It may help find recurrence earlier than standard scans.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.